196 related articles for article (PubMed ID: 34633840)
21. [Resistance profile and genetic barrier of dolutegravir].
Llibre JM; Clotet B
Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():20-5. PubMed ID: 25858608
[TBL] [Abstract][Full Text] [Related]
22. High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries.
Fokam J; Ngoufack Jagni Semengue E; Armenia D; Takou D; Dambaya B; Teto G; Chenwi CA; Nka AD; Beloumou GA; Ndjeyep SCD; Tchouaket MCT; Fainguem N; Sosso SM; Colizzi V; Perno CF; Ndjolo A; Ceccherini-Silberstein F; Santoro MM
Diagn Microbiol Infect Dis; 2022 Feb; 102(2):115574. PubMed ID: 34864527
[TBL] [Abstract][Full Text] [Related]
23. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
Mesplède T; Osman N; Wares M; Quashie PK; Hassounah S; Anstett K; Han Y; Singhroy DN; Wainberg MA
J Antimicrob Chemother; 2014 Oct; 69(10):2733-40. PubMed ID: 24917583
[TBL] [Abstract][Full Text] [Related]
24. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
Vavro C; Ruel T; Wiznia A; Montañez N; Nangle K; Horton J; Buchanan AM; Stewart EL; Palumbo P
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164521. PubMed ID: 34694878
[TBL] [Abstract][Full Text] [Related]
25. Low-cost urine tenofovir assay to triage dolutegravir resistance testing.
Martinson T; Nwogu-Attah J; Spinelli M; Gandhi M
Lancet HIV; 2024 May; 11(5):e282-e283. PubMed ID: 38461845
[No Abstract] [Full Text] [Related]
26. Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.
Seatla KK; Choga WT; Mogwele M; Diphoko T; Maruapula D; Mupfumi L; Musonda RM; Rowley CF; Avalos A; Kasvosve I; Moyo S; Gaseitsiwe S
PLoS One; 2019; 14(11):e0224292. PubMed ID: 31751353
[TBL] [Abstract][Full Text] [Related]
27. Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors.
Zhang WW; Cheung PK; Oliveira N; Robbins MA; Harrigan PR; Shahid A
J Infect Dis; 2018 Oct; 218(11):1773-1776. PubMed ID: 30010985
[TBL] [Abstract][Full Text] [Related]
28. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.
Han YS; Mesplède T; Wainberg MA
Infect Genet Evol; 2016 Dec; 46():286-291. PubMed ID: 27353185
[TBL] [Abstract][Full Text] [Related]
29. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
30. Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572).
Vavro C; Hasan S; Madsen H; Horton J; DeAnda F; Martin-Carpenter L; Sato A; Cuffe R; Chen S; Underwood M; Nichols G
Antimicrob Agents Chemother; 2013 Mar; 57(3):1379-84. PubMed ID: 23295935
[TBL] [Abstract][Full Text] [Related]
31. INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay.
Smith SJ; Ferris A; Zhao X; Pauly G; Schneider JP; Burke TR; Hughes SH
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960770
[TBL] [Abstract][Full Text] [Related]
32. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.
Brenner BG; Thomas R; Blanco JL; Ibanescu RI; Oliveira M; Mesplède T; Golubkov O; Roger M; Garcia F; Martinez E; Wainberg MA
J Antimicrob Chemother; 2016 Jul; 71(7):1948-53. PubMed ID: 27029845
[TBL] [Abstract][Full Text] [Related]
33. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
[TBL] [Abstract][Full Text] [Related]
34. Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.
Revollo B; Viñuela L; de la Mora L; García F; Noguera-Julián M; Parera M; Paredes R; Llibre JM
J Antimicrob Chemother; 2022 May; 77(6):1738-1740. PubMed ID: 35274144
[TBL] [Abstract][Full Text] [Related]
35. Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
Margot NA; Ram RR; White KL; Abram ME; Callebaut C
J Med Virol; 2019 Dec; 91(12):2188-2194. PubMed ID: 31389026
[TBL] [Abstract][Full Text] [Related]
36. Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.
Karabay O
AIDS; 2024 Jul; 38(8):1273. PubMed ID: 38814717
[No Abstract] [Full Text] [Related]
37. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort.
Abdullahi A; Kida IM; Maina UA; Ibrahim AH; Mshelia J; Wisso H; Adamu A; Onyemata JE; Edun M; Yusuph H; Aliyu SH; Charurat M; Abimiku A; Abeler-Dorner L; Fraser C; Bonsall D; ; Kemp SA; Gupta RK
J Antimicrob Chemother; 2023 Aug; 78(8):2000-2007. PubMed ID: 37367727
[TBL] [Abstract][Full Text] [Related]
38. Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
Chitongo R; Obasa AE; Mikasi SG; Jacobs GB; Cloete R
PLoS One; 2020; 15(5):e0223464. PubMed ID: 32379830
[TBL] [Abstract][Full Text] [Related]
39. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
[TBL] [Abstract][Full Text] [Related]
40. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]